Search

Displaying results 791 - 800 of 948 in total
  1. Drug

    Ethinylestradiol

    go.drugbank.com/drugs/DB00977
    ApprovedInvestigational

    Ethinylestradiol was first synthesized in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering. It was developed in an effort to create an estrogen with greater oral bioavailability. These properties were achieved by the substitu...

    Mixtures: PIL KB HARMONIS, PIL KB I KOMBINASIProducts: NAVEEN
  2. Drug

    Vapitadine

    go.drugbank.com/drugs/DB05738
    Experimental

    An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses.

  3. Drug

    Zinc gluconate

    go.drugbank.com/drugs/DB11248
    ApprovedInvestigationalVet approved

    It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and with decreased symptom severity.

  4. Drug

    Undecylenic acid

    go.drugbank.com/drugs/DB11117
    Approved

    Salts of undecylenate are found in topical over-the-counter or mixture products as antifungal agents.

  5. Drug

    Tetryzoline

    go.drugbank.com/drugs/DB06764
    Approved

    Tetryzoline is found in a wide array of over-the-counter eye drops, including the most common brand, Visine. … [A231769] Available since the 1950s, tetryzoline is a selective α<sub>1</sub>-receptor agonist [A231774] that is used as an ocular and nasal decongestant.

    Categories: Adrenergic alpha-1 Receptor Agonists
  6. Drug

    Pramipexole

    go.drugbank.com/drugs/DB00413
    ApprovedInvestigational

    common neurodegenerative disorders and causes a high level of disability in patients [A176855], leading to increased difficulty in performing activities of daily living due to symptoms that progress over

    Categories: Nonergot-derivative Dopamine Receptor Agonists
  7. Drug

    Plazomicin

    go.drugbank.com/drugs/DB12615
    Approved

    However, acquired resistance of aminoglycosides may arise through over expression of efflux pumps and ribosomal modification by bacteria, which results from amino acid or rRNA sequence mutations [A33942

  8. Drug

    Mycophenolate mofetil

    go.drugbank.com/drugs/DB00688
    ApprovedInvestigational

    A180799,A180805] Previously, mycophenolic acid (MPA) was administered to individuals with autoimmune diseases beginning in the 1970s, but was discontinued due to gastrointestinal effects and concerns over

  9. Drug

    Vedolizumab

    go.drugbank.com/drugs/DB09033
    ApprovedInvestigational

    [A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter. … however, the selective activity of vedolizumab against α4β7 integrin has been thought to contribute to its more favorable safety profile compared to its predecessor natalizumab, the first integrin receptor

    Categories: Integrin Receptor Antagonist
  10. Drug

    Opicapone

    go.drugbank.com/drugs/DB11632
    ApprovedInvestigational

    [A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) inhibitor (eg carbidopa) experience motor complications over time, which calls for the management